Medical device giant St. Jude Medical (NYSE:STJ) landed an important win today after a research team released study results finding that the company’s Durata defibrillator leads proved safe and reliable in an independent review.
Heart Rhythm Society
Boston Scientific hits 52-week high on Watchman trial results
"Bet BSX wishes that they had skipped ACC2013," wrote 1 wag today at the Heart Rhythm Society’s annual meeting, after Boston Scientific presented clinical trial results showing that its Watchman device is safer and more effective than the anticoagulant drug Warfarin.
The news sent BSX shares to $8.25 apiece today, up 10.9% over yesterday’s $7.44-per-share close, representing a new 52-week high for the stock. Shares were trading at $8.23 as of about 3:25 p.m., up 5.1% for the day.
HRS 2013: Heart failure doesn’t worsen with St. Jude’s recalled QuickSite CRT leads
Will another Durata failure report drag St. Jude down?
Wall Street didn’t move much on news of another insulation-related failure in St. Jude Medical’s (NYSE:STJ) next-generation Durata defibrillator leads this week.
When we mix politics with science
Today I opened an e-mail dated 4 October 2012 from the Heart Rhythm Society that announced the 2013 Keynote Speaker at the Heart Rhythm Society’s Opening Plenary Session 8 May 2013 in Denver, Colorado : Former President of the United States, Bill Clinton. Our society’s justification for this speaker reads as follows:
DOJ hands Heart Rhythm Society and hospitals its decision on defibrillators
Today, the Heart Rhythm Society issued the following cryptic email to its membership explaining the results of the three-year investigation by the Department of Justice (DOJ) audit of implantable cardiac defibrillator (ICD) implantation procedures:
A new day: Interim thoughts on the 2012 Heart Rhythm Society scientific sessions
I woke this morning to sunshine pouring through my hotel window as the heavy clouds of the last several days in Boston have disappeared. A whole new day has arrived.
HRS 2012: New imaging may better predict who needs an ICD | MassDevice.com On Call
MASSDEVICE ON CALL — A new imaging tool could help cardiologists better determine which patients are at the highest risk of sudden cardiac arrest and would most likely benefit from receiving an implanted cardioverter defibrillator, according to researchers at the University of Buffalo.
The researchers reported the findings of the UB Parapet study, touted as the largest PET study imaging study ever done on cardiac arrest, at this year’s Heart Rhythm Society meeting.
MassDevice.com +3 | The top 3 med-tech stories for May 10, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
HRS 2012: St. Jude calms fears about Durata lead, touts 10-year ICD study
St. Jude Medical (NYSE:STJ) tried to distance its Durata defibrillator leads from their troubled Riata predecessor and unveiled the results of the decade-long SCD-HeFT heart failure study during separate presentations at this year’s Heart Rhythm Society meeting in Boston, Mass.
HRS 2012 UPDATE: Riata’s survival rate ‘significantly worse’
A study comparing recalled defibrillator leads made by St. Jude Medical (NYSE:STJ) with 1 from rival Medtronic (NYSE:MDT) found 1 St. Jude model’s survival rate to be "significantly worse."